StockNews.com began coverage on shares of Aptose Biosciences (NASDAQ:APTO – Free Report) (TSE:APS) in a report released on Wednesday. The brokerage issued a hold rating on the biotechnology company’s stock.
APTO has been the subject of several other reports. Canaccord Genuity Group lowered their target price on Aptose Biosciences from $15.00 to $6.00 and set a buy rating for the company in a report on Thursday, May 16th. Piper Sandler reiterated an overweight rating and set a $5.00 price objective on shares of Aptose Biosciences in a research report on Wednesday, April 3rd. Finally, HC Wainwright reiterated a buy rating and set a $7.00 price objective on shares of Aptose Biosciences in a research report on Friday, June 14th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of Moderate Buy and an average target price of $14.83.
View Our Latest Stock Report on Aptose Biosciences
Aptose Biosciences Stock Performance
Aptose Biosciences (NASDAQ:APTO – Get Free Report) (TSE:APS) last posted its earnings results on Tuesday, May 14th. The biotechnology company reported ($0.73) EPS for the quarter, beating the consensus estimate of ($0.82) by $0.09. As a group, analysts predict that Aptose Biosciences will post -2.62 EPS for the current fiscal year.
Institutional Investors Weigh In On Aptose Biosciences
An institutional investor recently bought a new position in Aptose Biosciences stock. Texas Capital Bank Wealth Management Services Inc bought a new position in Aptose Biosciences Inc. (NASDAQ:APTO – Free Report) (TSE:APS) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 12,448 shares of the biotechnology company’s stock, valued at approximately $32,000. Texas Capital Bank Wealth Management Services Inc owned 0.16% of Aptose Biosciences at the end of the most recent reporting period. 26.62% of the stock is owned by hedge funds and other institutional investors.
Aptose Biosciences Company Profile
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
See Also
- Five stocks we like better than Aptose Biosciences
- Dividend Capture Strategy: What You Need to Know
- Why Call Options Volume for These 2 Stocks Spiked Together
- Earnings Per Share Calculator: How to Calculate EPS
- MarketBeat Week in Review – 7/22 – 7/26
- Insider Selling Explained: Can it Inform Your Investing Choices?
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.